aTyr Pharma
ATYRATYR · Stock Price
Historical price data
Overview
aTyr Pharma is translating the groundbreaking discovery of extracellular tRNA synthetase biology into a new class of protein-based therapeutics for fibrosis and inflammation. Its lead asset, efzofitimod, has reported Phase 3 topline results in pulmonary sarcoidosis and is in a Phase 2 study for SSc-ILD, targeting diseases with high unmet need. The company's strategy is to advance its proprietary platform to generate a pipeline of immunomodulators while exploring bispecific antibody opportunities through its Pangu BioPharma subsidiary.
Technology Platform
Platform based on extracellular domains of aminoacyl-tRNA synthetases (AARS), naturally occurring immunomodulators, to develop protein therapeutics for inflammation and fibrosis.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Efzofitimod 1 mg/kg + Efzofitimod 3 mg/kg + Placebo | SARS-CoV-2 (COVID-19) Severe Pneumonia | Phase 2 | |
| efzofitimod 450 mg + efzofitimod 270 mg + Placebo | Interstitial Lung Disease | Phase 2 | |
| ATYR1940 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1/2 | |
| ATYR1940 | Facioscapulohumeral Muscular Dystrophy | Phase 1/2 | |
| Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or ... | Pulmonary Sarcoidosis | Phase 1/2 |
Funding History
5Opportunities
Risk Factors
Competitive Landscape
In pulmonary sarcoidosis, efzofitimod faces competition only from generic steroids and immunosuppressants, positioning it as a potential first-in-class therapy. In SSc-ILD, it competes with the approved anti-fibrotic nintedanib but with a distinct immunomodulatory mechanism.
Company Timeline
Founded in San Diego, United States
Series B: $51.0M
Series C: $60.0M
IPO — $60.0M